Igor Odintsov

Igor Odintsov, MD

Assistant Professor
Pathology
Division
Surgical Pathology; Clinical Cancer Genomics Laboratory
Specialty Areas
Pulmonary Pathology
Molecular Pathology
[email protected]
Phone
415-502-6374
Fax
415-353-1612
https://profiles.ucsf.edu/igor.odintsov

505 Parnassus Ave
San Francisco, CA 94143
United States

Hospital Affiliations
UCSF Parnassus Heights
UCSF Mount Zion
Selected Publications
  1. Odintsov, I., Tazelaar, H. D., Lee, J. C., Damon, L. E., Devine, W. P., & Jones, K. D. (2026). Novel BRAF fusion in Erdheim-Chester disease with pulmonary manifestations: Importance of RNA-based testing and response to MEK inhibition. Histopathology, 10.1111/his.70170. Advance online publication. https://doi.org/10.1111/his.70170
  2. Odintsov, I., Siegmund, S. E., Pecci, F., Ricciuti, B., LoPiccolo, J., Sands, J. M., Wang, C. I., Sholl, L. M., & Dong, F. (2026). Clinical Utility of Next-Generation Sequencing in Tumors Diagnosed as Lung Squamous Cell Carcinoma: Real-World Data of Diagnostic and Therapeutic Implications. Modern pathology, 39(5), 100985. Advance online publication. https://doi.org/10.1016/j.modpat.2026.100985
  3. Kwok, A., Papke, D. J., Jr, & Odintsov, I. (2026). Cardiac epithelioid hemangioendothelioma with WWTR1::ACTL6A fusion and atypical histology mimicking cardiac angiosarcoma. Histopathology, 88(6), 1274–1277. https://doi.org/10.1111/his.70087
  4. Odintsov, I., Hammer, M. M., Ricciuti, B., Pecci, F., Awad, M. M., Dellaripa, P. F., & Sholl, L. M. (2025). The Genomic Landscape of NSCLC in Systemic Sclerosis Reveals Frequent TP53 Mutations and a Paucity of Actionable Oncogenes. Journal of thoracic oncology, S1556-0864(25)02855-2. Advance online publication. https://doi.org/10.1016/j.jtho.2025.10.008
  5. Odintsov, I., Siegmund, S. E., Mahadevan, N. R., Church, A. J., Sholl, L. M., & Nowak, J. A. (2025). A Novel Mutational Signature in Cancers Following Solid Organ or Allogeneic Stem Cell Transplantation. Modern pathology, 100921. Advance online publication. https://doi.org/10.1016/j.modpat.2025.100921
  6. Nakazawa, S., Pecci, F., Odintsov, I. (co-first author), Gazgalis, D., Gottlieb, F. H., Ricciuti, B., Zullo, L., Alessi, J. V., Di Federico, A., Aldea, M., Garbo, E., Gandhi, M. M., Saini, A., Feng, W. W., Jiang, J., Baldacci, S., Facchinetti, F., Makarem, M., Locquet, M. A., Haratani, K., … Awad, M. M. (2025). Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements. Cancer discovery, 15(6), 1129–1140. https://doi.org/10.1158/2159-8290.CD-24-1726
  7. Odintsov, I., Kleijn, T. G., Ryall, S. T., Ameline, B., Dong, F., Szuhai, K., Baumhoer, D., Dal Cin, P., Cleven, A. H. G., & Papke, D. J., Jr (2025). Odontogenic Myxoma Harbors Widespread Loss of Heterozygosity and Not Trisomies. The American journal of surgical pathology, 10.1097/PAS.0000000000002379. Advance online publication. https://doi.org/10.1097/PAS.0000000000002379
  8. Febres-Aldana, C. A., Vojnic, M., Odintsov, I. (co-first author), Zhang, T., Cheng, R., Beach, C. Z., Lu, D., Mattar, M. S., Gazzo, A. M., Gili, L., Harshan, M., Ameri, A., Machnicki, S., Xiao, X., Lockwood, W. W., Zhou, X. Y., Yao, Q., Drilon, A., Rekhtman, N., Shah, N., … Somwar, R. (2025). Pan-cancer analysis of oncogenic MET fusions reveals distinct pathogenomic subsets with differential sensitivity to MET-targeted therapy. Cancer discovery, 10.1158/2159-8290.CD-24-0417. Advance online publication. https://doi.org/10.1158/2159-8290.CD-24-0417
  9. Odintsov, I., Davis, D., Pissaloux, D., Tirode, F., de la Fouchardiere, A., & Hanna, J. (2025). BRAF Gene Fusions in Melanoma: First Kinase Domain Duplication, New Fusion Partners, and Clinical Outcomes. The American journal of surgical pathology, 10.1097/PAS.0000000000002370. Advance online publication. https://doi.org/10.1097/PAS.0000000000002370
  10. Odintsov, I., Papke, D. J., George, S., Padera, R. F., Hornick, J. L., & Siegmund, S. E. (2025). Genomic Profiling of Cardiac Angiosarcoma Reveals Novel Targetable KDR Variants, Recurrent MED12 Mutations and a High Burden of Germline POT1 Alterations. Clinical cancer research: an official journal of the American Association for Cancer Research, 10.1158/1078-0432.CCR-24-3277. Advance online publication. https://doi.org/10.1158/1078-0432.CCR-24-3277
  11. Odintsov, I., Isaacson, A., Fritchie, K. J., Hung, Y. P., Khoshnoodi, P., Sholl, L. M., Fletcher, C. D. M., & Anderson, W. J. (2024). Clear Cell Stromal Tumor of Lung: A Clinicopathologic, Immunohistochemical, and Molecular Characterization of 8 Cases. Modern pathology. Advance online publication. https://doi.org/10.1016/j.modpat.2024.100632
  12. Lu, M. Y., Chen, B., Williamson, D. F. K., Chen, R. J., Liang, I., Ding, T., Jaume, G., Odintsov, I., Le, L. P., Gerber, G., Parwani, A. V., Zhang, A., & Mahmood, F. (2024). A visual-language foundation model for computational pathology. Nature medicine 30(3), 863–874. https://doi.org/10.1038/s41591-024-02856-4
  13. Odintsov, I., Makarem, M., Nishino, M., Bachert, S. E., Zhang, T., LoPiccolo, J., Paweletz, C. P., Gokhale, P. C., Ivanova, E., Saldanha, A., Rudin, C. M., Lockwood, W. W., Ladanyi, M., Somwar, R., Jänne, P. A., & Sholl, L. M. (2023). Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC. Journal of thoracic oncology, S1556-0864(23)02428-0. Advance online publication. https://doi.org/10.1016/j.jtho.2023.12.019
  14. Odintsov, I., & Sholl, L. M. (2024). Prognostic and predictive biomarkers in non-small cell lung carcinoma. Pathology, 56(2), 192–204. https://doi.org/10.1016/j.pathol.2023.11.006
  15. Miyazaki, I. & Odintsov, I. (co-first author), Ishida, K., Lui, A. J. W., Kato, M., Suzuki, T., Zhang, T., Wakayama, K., Kurth, R. I., Cheng, R., Fujita, H., Delasos, L., Vojnic, M., Khodos, I., Yamada, Y., Ishizawa, K., Mattar, M. S., Funabashi, K., Chang, Q., Ohkubo, S., … Somwar, R. (2023). Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations. Nature cancer, 4(9), 1345–1361. 10.1038/s43018-023-00630-y. PMID: 37743366
  16. Udagawa, H., Nilsson, M. B., Robichaux, J. P., He, J., Poteete, A., Jiang, H., Heeke, S., Elamin, Y. Y., Shibata, Y., Matsumoto, S., Yoh, K., Okazaki, S., Masuko, T., Odintsov, I., Somwar, R., Ladanyi, M., Goto, K., & Heymach, J. V. (2023). HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies. Journal of thoracic oncology. S1556-0864(23)00802-X. Advance online publication. doi.org/10.1016/j.jtho.2023.08.034 PMID: PMID: 37678511
  17. Odintsov, I., Dong, F., Guenette, J.P., Fritchie, K.F., Jo, V.Y., Fletcher, C.D.M., Papke, D. Infantile Sinonasal Myxoma Is Clinically and Genetically Distinct From Other Myxomas of the Craniofacial Bones and From Desmoid Fibromatosis (2023). The American Journal of Surgical Pathology. 1;47(11):1301-1315. DOI: 10.1097/PAS.0000000000002119. PMID: 37678343
  18. Lo YC, Bauer AH, Odintsov I, Siegmund SE, Sholl LM, Dong F. Integrating Molecular Sequencing Into the Pathological Diagnosis of Clinically Suspected Non-Small Cell Lung Carcinomas. Mod Pathol. 2023 May;36(5):100126. doi: 10.1016/j.modpat.2023.100126. Epub 2023 Feb 7. PMID: 36842187.
  19. Odintsov, I., Jagannathan, J.P., Al-Ibraheemi, A., Selig, M.K., Newman, E.T., Fletcher, C.D.M., Nielsen, G.P., Hornick, J.L. Primary Clear Cell Sarcoma of Bone: Clinicopathologic Study of a Rare Presentation (2022). The American Journal of Surgical Pathology, in press. doi: 10.1097/PAS.0000000000001988.
  20. Schram, A.M & Odintsov, I. (co-first author), Lui, A.J.W., Khodos, I., Mattar, M.S., de Stanchina, E., Drilon, A., Ladanyi, M. and R. Somwar. Zenocutuzumab, a HER2xHER3 bi- specific antibody is effective in patients with NRG1-rearranged cancers (2022). Cancer Discovery 2;12(5):1233-1247. Doi: 10.1158/2159-8290.CD-21-1119. PMID: 35135829.
  21. Odintsov, I., Ortiz, M.V., Khodos, I., Mattar, M.S., Lui, A.J.W., Kohsaka, S., de Stanchina, E., Glade Bender, J.L., Ladanyi, M. and R. Somwar. CIC-mediated modulation of MAPK signaling in kinase-addicted sarcomas opposes RTK inhibitor response and provides a rationale for co-inhibition of the MAPK pathway (2022). Cancer Research 82 (6): 1110-1127. Doi: 10.1158/0008-5472.CAN-21-1397. PMID: 35074756.
  22. Smith, R.S. & Odintsov, I. (co-first author), Liu, Z., Lui, A.J.W., Hayashi, T., Vojnic, M., Suehara, Y., Delasos, L., Mattar, M.S., Hmeljak, J., Ramirez, H.A., Shaw, M., Bui, G., Hartono, A.B., Gladstone, E., Kunte, S., Magnan, H., Khodos, I., De Stanchina, E., La Quaglia, M.P., Yao, J., Lae, M., Lee, S.B., Spraggon, L., Pratilas, C.A., Ladanyi, M. and R. Somwar. Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling. (2022). Disease Models and Mechanisms 15 (1): dmm047621. Doi: 10.1242/dmm.047621. PMID: 34841430.
  23. Odintsov, I., Mattar, M.S., Lui, A.J.W., Offin, M., Kurzatkowski, C., Delasos, L., Khodos, Asher, M., Daly, R.M, Rekhtman, N., De Stanchina, E., Ganji, G., Ladanyi, M. and R. Somwar. Novel preclinical patient-derived lung cancer models reveal inhibition of ERBB3 and MTOR signaling as therapeutic strategies for NRG1 fusion-positive cancers (2021). Journal of Thoracic Oncology 16 (7): 1149-1165. Doi: 10.1016/j.jtho.2021.03.013. PMID: 33839363.
  24. Odintsov, I., Lui, A.J.W., Sisso, W.J., Gladstone, E., Liu, Z., Delasos, L., Kurth, R.I., Sisso, E.M., Vojnic, M., Khodos, I., Mattar, M.S., de Stanchina, E., Leland, S. M., Ladanyi, M. and R. Somwar. The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with oncogenic NRG1 fusions (2021). Clinical Cancer Research 27 (11): 3154-3166. doi: 10.1158/1078-0432.CCR-20-3605. PMID: 33824166.
  25. Odintsov, I., Somwar, R., Ladanyi, M. and A. Drilon. ROS1 at the Crossroads of Clinical Oncology, Molecular Diagnostics and Drug Development (2021). JCO Oncology Practice: 15-16 2021. Doi: 10.1200/OP.20.00969. PMID: 33434449.
  26. Hayashi, T., Odintsov, I. (co-first author), Smith, R.S., Ishizawa, K., Lui, J.W.A., Delasos, L., Kurzatkowski, C., Tai, H., Gladstone, E., Vojnic, M., Kohsaka, S., Suzawa, K., Liu Z., Mattar, M.S., Khodos, I., Davare, M.A., Drilon, A., Cheng, E., de Stanchina, E., Ladanyi, M. and R. Somwar. RET inhibition in novel patient-derived models of RET-fusion positive lung adenocarcinoma reveals a role for MYC upregulation (2020). Disease Models and  Mechanism 14 (2): dmm047779. Doi: 10.1242/dmm.047779. PMID: 33318047.